FormsNet3 - Blank Form


 
 
Sequence Number:    

 
 
Date Received: __ __ __ __ - __ __- __ __  

 
 
CIBMTR Center Number    

 
 
CIBMTR Recipient ID:    

 
 
Today's Date: __ __ __ __ - __ __- __ __  

 
 
Date of HSCT for which this form is being completed: __ __ __ __ - __ __- __ __  

 

HSCT type:(check all that apply) 

 
  

gfedcb
Autologous

 
 

  
gfedcb

Allogeneic, unrelated

 
 

  
gfedcb

Allogeneic, related

 
 

  
gfedcb

Syngeneic (identical twin)

 

Product type: (check all that apply) 

 
  

gfedcb
Marrow

 
 

  
gfedcb

PBSC

 
 

  
gfedcb

Cord blood

 
 

  
gfedcb

Other product

 
 
Specify:    

 
 
Visit:

 nmlkji
100 day  

 nmlkji
6 months  

 nmlkji
1 year  

 nmlkji
2 years  

 nmlkji
> 2 years,  

 
 
Specify:    

 
1  Compared to the disease status prior to the preparative regimen, what was the best response since the date of the last report? (Include response to any post-HSCT treatment 

planned as of Day 0.) 

    
 nmlkji

complete response - no primary tumor, no metasraric sites, catecholamines normal; included continued complete response  

 nmlkji
very good partial response - primary tumor decreased by 90-99%, no metastatic sites, catecholamines normal; residual 99Tc bone changes allowed  

 nmlkji
partial response - primary tumor decreased by > 50%, all measurable metastatic sites decreased by > 50%, number of positive bone sites decreased by > 50%, no more than 

1 positive bone marrow site allowed, 1 positve marrow aspirate or biopsy allowed if this represents a decrease from the number of postive sites at diagnosis  

 nmlkji
minimal response - no new lesion; > 50% reduction of any measurable lesion (primary or metastases) with < 50% reduction in any other; < 25% increase in any existing 

lesion  

 nmlkji
no response - no new lesions; < 50% reduction but < 25% increase in any existing lesion  

 nmlkji
progressive disease - any new lesions; increase of any measurable lesion by > 25%; previous negative marrow positive for tumor  

 nmlkji
Not assessed  

 nmlkji
unknown / not tested  

 

Specify the site(s) of persistent tumor: 

 
2  Adrenal gland

    
 nmlkji

yes  
 nmlkji

no  

 
 

3  Bone

    
 nmlkji

yes  
 nmlkji

no  

 
 

4  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  

Key Fields 

Disease Assessment at the Time of Best Response to HSCT Questions: 1 - 159

Form 2126 R2.0: Neuroblastoma Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2126 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 1 / 8



 
 

5  Cerebellum

    
 nmlkji

yes  
 nmlkji

no  

 
 

6  Cerebrospinal fluid (CSF)

    
 nmlkji

yes  
 nmlkji

no  

 
 

7  Cerebrum

    
 nmlkji

yes  
 nmlkji

no  

 
 

8  Cranial nerves

    
 nmlkji

yes  
 nmlkji

no  

 
 

9  Liver

    
 nmlkji

yes  
 nmlkji

no  

 
 

10  Lymph node

    
 nmlkji

yes  
 nmlkji

no  

 
 

11  Mediastinum

    
 nmlkji

yes  
 nmlkji

no  

 
 

12  Paraspinal ganglion

    
 nmlkji

yes  
 nmlkji

no  

 
 

13  Retro-orbital area

    
 nmlkji

yes  
 nmlkji

no  

 
 

14  Skin / subcutaneous tissue

    
 nmlkji

yes  
 nmlkji

no  

 
 

15  Elevated catecholemines

    
 nmlkji

yes  
 nmlkji

no  

 
 

16  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
17  Specify other site:    

  
 
18  Specify the date best response was determined: __ __ __ __ - __ __- __ __  

 
  

gfedcb
Date previously reported

 
 

19  Were tumor markers evaluated for the best response post-HSCT determination?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the following tumor marker analyses performed: 
 

20  Homovanilic acid (HVA):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
21     

 <!--[endif]-->µg/mg creatinine 

 
 
22  Date of best response determination: __ __ __ __ - __ __- __ __  

 
 

23  Neuron specific enolase:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
24     

ng/mL 

 
 
25  Date of best response determination: __ __ __ __ - __ __- __ __  

 
 

26  Serum ferritin:

    
 nmlkji

Known  
 nmlkji

Not known  

Form 2126 R2.0: Neuroblastoma Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2126 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 2 / 8



 
 
27     

ng/mg or µg/L 

 
 
28  Date of best response determination: __ __ __ __ - __ __- __ __  

 
 

29  Vanilmandelic acid (VMA):

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
30     µg/mg creatinine 

 
 
31  Date of best response determination: __ __ __ __ - __ __- __ __  

 
 

32  Other tumor marker analysis:

    
 nmlkji

Known  
 nmlkji

Not known  

 
 
33  Specify other analysis:    

 
 
34  Specify level and units:    

 
 

35  Was the recipient given planned therapy per protocol post-HSCT treatment for neuroblastoma?

    
 nmlkji

yes  
 nmlkji

no  

 
 

36  Was radiotherapy given?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the site(s) of radiotherapy: 

 
37  Bone metastases

    
 nmlkji

yes  
 nmlkji

no  

 
 

38  Primary tumor

    
 nmlkji

yes  
 nmlkji

no  

 
 

39  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
40  Specify:    

 
 
41  Specify the date radiotherapy was started: __ __ __ __ - __ __- __ __  

 
 
42  Number of fractions given:    

 
 
43  Dose per fraction:    

 <!--[endif]-->cGy (rads) 

 
 

44  Was MIBG given?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the radioisotope given: 

 
45  131I-MIBG

    
 nmlkji

yes  
 nmlkji

no  

 
 

46  Other

    
 nmlkji

yes  
 nmlkji

no  

 
 
47  Specify:    

 
 
48  Specify the date MIBG treatment was performed: __ __ __ __ - __ __- __ __  

 
 

49  Were retinoids given?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the retinoids given: 

 
50  Isotretinoin

    
 nmlkji

yes  
 nmlkji

no  

Form 2126 R2.0: Neuroblastoma Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2126 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 3 / 8



 
 

51  Other

    
 nmlkji

yes  
 nmlkji

no  

 
 
52  Specify:    

 
 
53  Specify the date retinoid therapy was started: __ __ __ __ - __ __- __ __  

 
 

54  Was immunotherapy given?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the drug (s) given: 
 

55  α-interferon

    
 nmlkji

yes  
 nmlkji

no  

 
 

56  Anti-GD2 anitbody CH14.18

    
 nmlkji

yes  
 nmlkji

no  

 
 

57  Interleukin-2 (IL-2)

    
 nmlkji

yes  
 nmlkji

no  

 
 

58  Other

    
 nmlkji

yes  
 nmlkji

no  

 
 
59  Specify:    

 
 
60  Specify the date immunotherapy was started: __ __ __ __ - __ __- __ __  

 
 

61  Was chemotherapy given?

    
 nmlkji

yes  
 nmlkji

no  

 
 

62  Adriamycin

    
 nmlkji

yes  
 nmlkji

no  

 
 

63  Cisplatin

    
 nmlkji

yes  
 nmlkji

no  

 
 

64  Cyclophosphamide

    
 nmlkji

yes  
 nmlkji

no  

 
 

65  Dacarbazine (DTIC)

    
 nmlkji

yes  
 nmlkji

no  

 
 

66  Etoposide (VP-16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

67  Isosfamide

    
 nmlkji

yes  
 nmlkji

no  

 
 

68  Melphalan (L-PAM)

    
 nmlkji

yes  
 nmlkji

no  

 
 

69  Teniposide (VM26)

    
 nmlkji

yes  
 nmlkji

no  

 
 

70  Vincristine

    
 nmlkji

yes  
 nmlkji

no  

 
 

71  Other

    
 nmlkji

yes  
 nmlkji

no  

 
 
72  Specify:    

Form 2126 R2.0: Neuroblastoma Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2126 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 4 / 8



 
 
73  Specify the date chemotherapy was started: __ __ __ __ - __ __- __ __  

 
 

74  Was other treatment given?

    
 nmlkji

yes  
 nmlkji

no  

 
 
75  Specify other treatment:    

 
 
76  Specify the date other treatment was started: __ __ __ __ - __ __- __ __  

 
 

77  Did the neuroblastoma recur or progress since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the known site(s) of disease progression / recurrence: 

 
78  Adrenal gland

    
 nmlkji

yes  
 nmlkji

no  

 
 
79  Date determined: __ __ __ __ - __ __- __ __  

 
 

80  Bone

    
 nmlkji

yes  
 nmlkji

no  

 
 
81  Date determined: __ __ __ __ - __ __- __ __  

 
 

82  Bone marrow

    
 nmlkji

yes  
 nmlkji

no  

 
 
83  Date determined: __ __ __ __ - __ __- __ __  

 
 

84  Cerebellum

    
 nmlkji

yes  
 nmlkji

no  

 
 
85  Date determined: __ __ __ __ - __ __- __ __  

 
 

86  Cerebrospinal
fluid (CSF) 

    
 nmlkji

yes  
 nmlkji

no  

 
 
87  Date determined: __ __ __ __ - __ __- __ __  

 
 

88  Cerebrum

    
 nmlkji

yes  
 nmlkji

no  

 
 
89  Date determined: __ __ __ __ - __ __- __ __  

 
 

90  Cranial nerves

    
 nmlkji

yes  
 nmlkji

no  

 
 
91  Date determined: __ __ __ __ - __ __- __ __  

 
 

92  Liver

    
 nmlkji

yes  
 nmlkji

no  

 
 
93  Date determined: __ __ __ __ - __ __- __ __  

 
 

94  Lymph nodes

    
 nmlkji

yes  
 nmlkji

no  

 
 
95  Date determined: __ __ __ __ - __ __- __ __  

 
 

96  Mediastinum

    
 nmlkji

yes  
 nmlkji

no  

 
 
97  Date determined: __ __ __ __ - __ __- __ __  

 
 

98  Paraspinal ganglion

    
 nmlkji

yes  
 nmlkji

no  

 
 
99  Date determined: __ __ __ __ - __ __- __ __  

Form 2126 R2.0: Neuroblastoma Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2126 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 5 / 8



 
 

100  Retro-orbital area

    
 nmlkji

yes  
 nmlkji

no  

 
 
101  Date determined: __ __ __ __ - __ __- __ __  

 
 

102  Skin/subcutaneous tissue

    
 nmlkji

yes  
 nmlkji

no  

 
 
103  Date determined: __ __ __ __ - __ __- __ __  

 
 

104  Other site:

    
 nmlkji

yes  
 nmlkji

no  

 
 
105  Date determined: __ __ __ __ - __ __- __ __  

 
 
106  Specify other site:    

 

Specify the methods used to examine sites of disease recurrence / persistence / progression: 
 

107  Biopsy

    
 nmlkji

yes  
 nmlkji

no  

 
 

108  Specify disease status:

    
 nmlkji

Positive  
 nmlkji

Negative  

 
 

109  Bone scan

    
 nmlkji

yes  
 nmlkji

no  

 
 

110  Specify disease status:

    
 nmlkji

Positive  
 nmlkji

Negative  

 
 

111  Radiology

    
 nmlkji

yes  
 nmlkji

no  

 
 

112  Specify disease status:

    
 nmlkji

Positive  
 nmlkji

Negative  

 
 

113  Other method

    
 nmlkji

yes  
 nmlkji

no  

 
 

114  Specify disease status:

    
 nmlkji

Positive  
 nmlkji

Negative  

 
 
115  Specify other method:    

 
 

116  Was the recipient given treatment for post-HSCT persistent, progressive or recurrent disease since the date of the last report?

    
 nmlkji

yes  
 nmlkji

no  
 nmlkji

Unknown  

 
 

117  Was radiotherapy given?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the site(s) of radiotherapy: 
 

118  Bone metastases

    
 nmlkji

yes  
 nmlkji

no  

 
 

119  Primary tumor

    
 nmlkji

yes  
 nmlkji

no  

 
 
120  Other

 nmlkji
yes  

 nmlkji
no  

 
 
121  Specify:    

 
 
122  Specify the date radiotherapy was started: __ __ __ __ - __ __- __ __  

Form 2126 R2.0: Neuroblastoma Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2126 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 6 / 8



 
 
123  Number of fractions given:    

 
 
124  Dose per fraction:    

  <!--[endif]-->cGy (rads) 

 
 

125  Was MIBG given?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the radioisotope given: 
 

126  131I-MIBG

    
 nmlkji

yes  
 nmlkji

no  

 
 

127  Other

    
 nmlkji

yes  
 nmlkji

no  

 
 
128  Specify:    

 
 
129  Specify the date MIBG treatment was performed: __ __ __ __ - __ __- __ __  

 
 

130  Were retinoids given?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the retinoids given: 

 
131  Isoretinoin

    
 nmlkji

yes  
 nmlkji

no  

 
 

132  Other

    
 nmlkji

yes  
 nmlkji

no  

 
 
133  Specify:    

 
 
134  Specify the date retinoid therapy was started: __ __ __ __ - __ __- __ __  

 
 

135  Was immunotherapy given?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the drug(s) given: 
 

136  α-interferon

    
 nmlkji

yes  
 nmlkji

no  

 
 

137  Anti-GD2 antibody CH 14.18

    
 nmlkji

yes  
 nmlkji

no  

 
 

138  Interleuken-2 (IL-2)

    
 nmlkji

yes  
 nmlkji

no  

 
 

139  Other

    
 nmlkji

yes  
 nmlkji

no  

 
 
140  Specify:    

 
 
141  Specify the date immunotherapy was started: __ __ __ __ - __ __- __ __  

 
 

142  Was chemotherapy given?

    
 nmlkji

yes  
 nmlkji

no  

 

Specify the treatment(s) given: 

 
143  Adriamycin

    
 nmlkji

yes  
 nmlkji

no  

Form 2126 R2.0: Neuroblastoma Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2126 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 7 / 8



 
 

144  Cisplatin

    
 nmlkji

yes  
 nmlkji

no  

 
 

145  Cyclophosphamide

    
 nmlkji

yes  
 nmlkji

no  

 
 

146  Dacarbazine (DTIC)

    
 nmlkji

yes  
 nmlkji

no  

 
 

147  Etoposide (VP-16)

    
 nmlkji

yes  
 nmlkji

no  

 
 

148  Ifosfamide

    
 nmlkji

yes  
 nmlkji

no  

 
 

149  Melphalan (L-PAM)

    
 nmlkji

yes  
 nmlkji

no  

 
 

150  Tenoposide (VM26)

    
 nmlkji

yes  
 nmlkji

no  

 
 

151  Vincristine

    
 nmlkji

yes  
 nmlkji

no  

 
 

152  Other

    
 nmlkji

yes  
 nmlkji

no  

 
 
153  Specify:    

 
 
154  Specify the date chemotherapy was started: __ __ __ __ - __ __- __ __  

 
 

155  Was other treatment given?

    
 nmlkji

yes  
 nmlkji

no  

 
 
156  Specify other treatment:    

 
 
157  Specify the date other treatment was started: __ __ __ __ - __ __- __ __  

 
 

158  What is the current disease status?

    
 nmlkji

complete remission  

 nmlkji
Not in complete remission  

 
 
159  Specify the date the current disease status was determined: __ __ __ __ - __ __- __ __  

  
 
First Name:    

 
Last Name:    

  
 
Phone number:    

 
Fax number:    

 
 
E-mail address:    

Form 2126 R2.0: Neuroblastoma Post-HSCT Data  
Center:  CRID: 

                CIBMTR Form 2126 revision 2.0 last updated July 2007
Copyright(c) 2012 National Marrow Donor Program and  

The Medical College of Wisconsin, Inc. All rights reserved.  Page 8 / 8